This proposal focuses on neuroendocrine (NE) cells of the prostate and the role they play in promoting androgen-interdependent growth of prostate tumors. Neuroendocrine (NE) cells are fully differentiated, post- mitotic secretory cells that populate both normal and malignant prostate tissue. Morphologically, NE cells can be identified by their characteristic neuronal appearance, which includes the presence of long neuritic processes and dense secretory vesicles in the cell body. In prostate tumors the proliferative index of neoplastic epithelial cells surrounding the NE cells is also frequently elevated, suggesting that the NE cells act in a paracrine fashion by secreting growth-inducing factors and contributing toe the progression of the disease. Several of these factors have been identified and include serotonin, thyroid stimulating hormone (TSH), calcitonin, bombesin, and somatostatin. Increases in the number of NE cells occur as part of tumor progression, presumably. Increases in the number of NE cells occur as part of tumor progression, presumably due to the influence of both genetic and epigenetic factors. The origin of these increased number sin later stage prostatic carcinomas is uncertain, but several studies suggest that NE cells arise from within the tumor, either from a hyperplastic basal epithelial cell or from a transformed exocrine epithelial c4ll by de-differentiation or trans-differentiation, respectively. Bang have in fact shown that the prostate tumor cells, LNCaP and PC3M, can be induced to differentiate into post-mitotic NE-like cells upon addition for agents that increase intracellular cyclic AMP. These experiments provide evidence for the transdifferentiation model of NE cell derivation and suggest that physiological factors that elevate internal cAMP levels may play a role in the differentiation process. The goal of the studies described in this proposal is to identify physiological factors and critical signaling pathways that contribute to the differentiation of NE cells and to determine whether NE cells secrete paracrine signals which potential the growth of prostate carcinomas. To accomplish these aims, a panel of hormones and peptide factors that cause elevations in intracellular cAMP in LNCaP cells will be tested, and signaling pathways emanating from the most potent differentiating agents will be analyzed. In addition, a LacSwitch will be generated that directs the regulated expression of a constitutively active form of the catalytic subunit of protein kinase I and used to differentiated prostate tumor cell lines to NE cells. These differentiated cells will then be tested both in culture and in the animal for their ability to enhance proliferation of non-differentiated tumor cells. Finally, the signaling mechanisms regulating secretion will also be examined. The goals of the project are to elucidate signaling pathways that regulate differentiation and secretion of cell cells and to identify critical components of these pathways that could serve as molecular targets for the development of novel therapies for late stage, androgen-independent prostate tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA076465-04
Application #
6563900
Study Section
Subcommittee G - Education (NCI)
Project Start
2002-02-01
Project End
2003-01-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
4
Fiscal Year
2002
Total Cost
$199,030
Indirect Cost
Name
University of Virginia
Department
Type
DUNS #
001910777
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Axelrod, Mark J; Mendez, Rolando E; Khalil, Ashraf et al. (2015) Synergistic apoptosis in head and neck squamous cell carcinoma cells by co-inhibition of insulin-like growth factor-1 receptor signaling and compensatory signaling pathways. Head Neck 37:1722-32
DaSilva, John O; Amorino, George P; Casarez, Eli V et al. (2013) Neuroendocrine-derived peptides promote prostate cancer cell survival through activation of IGF-1R signaling. Prostate 73:801-12
Gioeli, Daniel; Wunderlich, Winfried; Sebolt-Leopold, Judith et al. (2011) Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration-resistant prostate cancer. Mol Cancer Ther 10:1581-90
Vomastek, Tomas; Iwanicki, Marcin P; Burack, W Richard et al. (2008) Extracellular signal-regulated kinase 2 (ERK2) phosphorylation sites and docking domain on the nuclear pore complex protein Tpr cooperatively regulate ERK2-Tpr interaction. Mol Cell Biol 28:6954-66
Casarez, Eli V; Dunlap-Brown, Marya E; Conaway, Mark R et al. (2007) Radiosensitization and modulation of p44/42 mitogen-activated protein kinase by 2-Methoxyestradiol in prostate cancer models. Cancer Res 67:8316-24
Deeble, Paul D; Cox, Michael E; Frierson Jr, Henry F et al. (2007) Androgen-independent growth and tumorigenesis of prostate cancer cells are enhanced by the presence of PKA-differentiated neuroendocrine cells. Cancer Res 67:3663-72
Gioeli, Daniel; Black, Ben E; Gordon, Vicki et al. (2006) Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization. Mol Endocrinol 20:503-15
Gioeli, Daniel (2005) Signal transduction in prostate cancer progression. Clin Sci (Lond) 108:293-308
Fu, Maofu; Rao, Mahadev; Wu, Kongming et al. (2004) The androgen receptor acetylation site regulates cAMP and AKT but not ERK-induced activity. J Biol Chem 279:29436-49
Cooper, Carlton R; Sikes, Robert A; Nicholson, Brian E et al. (2004) Cancer cells homing to bone: the significance of chemotaxis and cell adhesion. Cancer Treat Res 118:291-309

Showing the most recent 10 out of 20 publications